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Abstract
Background: Three different subsets of circulating human monocytes, CD14brightCD16- (classical), CD14brightCD16+
(intermediate), and CD14dimCD16+ (non-classical) have been recently identified. It has been reported that
CD14brightCD16+ monocytes are increased in rheumatoid arthritis (RA). However, the role of each monocyte
subset in the pathogenesis of RA is still unclear. The purpose of this study was to investigate the association of
CD14brightCD16+ monocytes with RA.
Methods: The study enrolled 35 patients with RA and 14 healthy volunteers. The three subsets of peripheral
blood monocytes were analyzed by flow cytometry. Serum cytokines were measured at baseline in patients
with RA and in healthy volunteers. CD14brightCD16- monocytes were isolated and cultured in vitro with
different cytokines for 14 hours, and CD16 induction was assessed.
Results: The proportion of CD14brightCD16+ monocytes, and serum interleukin (IL)-6, IL-8, and IL-10 were
increased in patients with RA compared to healthy controls. The proportion of CD14brightCD16+ monocytes
correlated with the disease activity of RA positively, whereas the proportion of CD14brightCD16- monocytes
correlated negatively. When isolated CD14brightCD16- monocytes were stimulated with IL-6, IL-8, and
IL-10, the only cytokine that significantly induced CD16 expression on the cells was IL-10.
Conclusions: The proportion of CD16brightCD14+ monocytes was positively correlated with RA disease activity.
The expression of CD16 in monocytes was induced by IL-10 but not IL-6, and IL-8 was enhanced in the sera of
patients with RA. Our results suggest that CD16brightCD14+ monocytes are involved in the pathogenesis of RA
and that IL-10 is a key cytokine that regulates CD16 expression in monocytes.
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Background
Rheumatoid arthritis (RA) is a systemic, autoimmune, and
chronic inflammatory disease which causes pain and dys-
function and leads to the destruction of joints [1]. The
major inflammatory tissue is the synovium, the thin tissue
that lines the joint. Immune cells, such as neutrophils, lym-
phocytes, and monocytes, produce inflammatory cytokines
including interleukin (IL)-1, tumor necrosis factor-α
(TNF-α), IL-6, and granulocyte-macrophage colony-
stimulating factor (GM-CSF) [2], and are involved in
the development of inflammation. It is well-known that
peripheral blood monocytes are derived from precur-
sors in the bone marrow, migrate into synovial tissue,
and differentiate into macrophages that produce pro-
inflammatory cytokines [3]. Macrophages involved in
synovial inflammation transform into osteoclasts, which
cause joint destruction in RA [2, 4]. Osteoclasts are also
derived from CD14+ monocytes under the influence of
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pro-inflammatory cytokines [5]. Circulating CD14+
monocytes serve as precursors of endothelial cells and
contribute to the process of angiogenesis in the tissue
[6]. Based on this background, the identification and
classification of peripheral monocytes responsible for
the disease is indispensable to understanding the patho-
genesis of RA.
CD16 is a receptor for immunoglobulin (Ig) gamma
Fc region III (FcγRIII). Fcγ receptors (FcγRs) are
expressed on most of the cells involved in the immune
system, including circulating monocytes, and they
regulate immune responses through interaction with
antibodies [7]. According to these previous studies, im-
mune complexes formed by anti-cyclic citrullinated
peptide antibody (ACPA) and citrullinated peptide
seem to bind to FcγRs and stimulate immune cell acti-
vation and release of inflammatory cytokines in pa-
tients with RA [8]. Therefore, FcγRIII is one of the
molecules possibly associated with the pathogenesis of
RA. It has been reported that aberrant expression of
FcγRIII, or the presence of allelic variants, can contrib-
ute to the pathogenesis of RA [9]. However, the regula-
tory mechanisms of FcγRIII in RA are not fully
understood.
Until now, circulating human monocytes have been
classified into CD14+ CD16- (classical) and CD14+
CD16+ subsets according to their expression levels of
CD14 and CD16 [10, 11]. It had been reported that
CD14+ CD16+ monocytes are increased in patients with
RA [12]. Recently, a new third monocyte subpopulation,
CD14brightCD16+ monocytes, was defined. According to
the new classification system, the CD14+ CD16+ popu-
lation is classified into CD14brightCD16+ (intermediate)
and CD14dimCD16+ (non-classical) monocytes, de-
pending on the level of CD14 expression [13]. The
CD14brightCD16- (classical) monocyte is the major
subset, while the CD14brightCD16+ and CD14dimCD16+
subsets occur in lower numbers than classical monocytes
[11].
It has been shown that the CD14brightCD16+ mono-
cyte population increases in inflammatory or infec-
tious conditions and, upon lipopolysaccharide
stimulation [14, 15], produces TNF-α, IL-1β, IL-6, and
IL-10. This newly classified CD14brightCD16+ mono-
cyte population has been reported to be increased in
patients with RA, whereas the CD14dimCD16+ mono-
cyte population is not increased [14]. It has been
suggested that CD14brightCD16+ monocytes may mi-
grate into the synovium from peripheral blood and
differentiate into M1 or M2 macrophages in the tissue
[16]. However, the role of each subset in RA has not
been fully clarified.
In this study, we sought to investigate the involvement
of CD14brightCD16+ monocytes in the pathogenesis of
RA, and possible mechanisms of the enhanced expres-
sion of CD16 on monocytes in patients with RA.
Methods
Subjects and study design
Patients with RA (n = 35) (mean age ± SD 59.8 ±
12.6 years, 82.9% female) who met the 2010 American
College of Rheumatology/European League Against
Rheumatism Classification criteria, and 14 healthy vol-
unteers (mean age 49.2 ± 10.8 (range 30–72), 12 female)
were enrolled into the study. All patients visited Keio
University Hospital between January 2013 and May 2014
and had never been treated with methotrexate (MTX) or
biological agents. They were considered to have moder-
ate or high disease activity (scoring ≥3.2 on the 28-joint
disease activity score based on erythrocyte sedimentation
rate (DAS28-ESR). All participants gave written in-
formed consent in accordance with the Declaration of
Helsinki. MTX was initiated at an oral dose of 4–16 mg
weekly. Monocyte subsets from peripheral blood samples
were taken at baseline and after 12 weeks of MTX treat-
ment in the patients. Clinical parameters including C-
reactive protein (CRP), ESR, matrix metalloproteinase-3
(MMP-3), ACPA, and rheumatoid factor (RF) titers were
obtained by routine clinical laboratory methods. DAS28-
ESR scores, DAS28-CRP score, clinical disease activity
index (CDAI), and simplified disease activity index (SDAI)
were also determined at baseline and after 12 weeks of
MTX treatment. Clinical characteristics of the patients
were retrospectively collected from their medical records.
Monocyte subset determination
Heparinized whole blood was stained with phycoerythrin-
Cy7 (PE-Cy7)-conjugated anti-CD14 (clone M5E2, BD
Pharmingen, San Diego, CA, USA) and V450-conjugated
anti-CD16 antibodies (clone 3G8, BD Horizon, San Jose,
CA, USA), and analyzed using a flow cytometer with
built-in software (MACSQuant Analyzer® and MACS-
Quantify® software, Miltenyi Biotec, Bergisch Gladbach,
Germany). Monocyte subsets were identified on the basis
of forward scatter/side scatter characteristics and CD14-
positive gating. Subpopulations of CD14brightCD16-,
CD14brightCD16+, and CD14dimCD16+ monocytes were
distinguished by their surface expression pattern of CD14
and CD16 according to a previous report [11] and the
proportion of each monocyte subset was determined.
Serum immunoassays
Serum samples were collected at baseline and stored at
-80 °C. Serum levels of GM-CSF, interferon-γ (IFN-γ),
IL-1β, IL-10, IL-12p70, IL-2, IL-6, IL-8, and TNF-α were
measured by multiplex electrochemiluminescence assay
(Meso Scale Discovery SECTOR Imager 2400 platform®,
Meso Scale Discovery, Rockville MD, USA). Serum
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macrophage colony-stimulating factor (M-CSF) levels
were assessed by enzyme-linked immunosorbent assay
(ELISA) (Quantikine® ELISA, Human M-CSF Immuno-
assay, R&D Systems Inc., Minneapolis MN, USA) and
calculated using the manufacturer’s software. Values are
expressed in pg/mL and presented as median with inter-
quartile range (IQR).
Stimulation of peripheral monocytes in vitro
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from five healthy volunteers by density gradient
centrifugation (Ficoll-Paque®, GE Healthcare, Uppsala,
Sweden). To isolate monocyte subsets, cells were stained
with phycoerythrin (PE)-conjugated anti-CD14 (clone
MφP9, BD Pharmingen) and BV421-conjugated anti-
CD16 antibodies (clone 3G8, BD Horizon) and sorted
according to their CD14/CD16 expression using a cell
sorter (BD Aria III®, BD Biosciences, San Jose CA, USA).
CD14brightCD16- monocytes were cultured at 2.5 × 105/
500 μL in Roswell Park Memorial Institute medium
(RPMI-1640®, ATCC, Manassas, VA, USA) with 10%
heat-inactivated fetal bovine serum (MP Biomedicals,
Santa Ana CA, USA). They were then stimulated for
14 hours with either 100 ng/mL M-CSF, 1-100 (1, 10,
25, 50, or 100) ng/mL IL-10, 100 ng/mL IL-6, or 20 ng/
mL IL-8 at 37 °C in a humidified atmosphere contain-
ing 5% CO2. The stimulated monocytes were stained
with PE-conjugated anti-CD14, BV421-conjugated
anti-CD16, and allophycocyanin (APC)-conjugated
anti-HLA (human leukocyte antigen)-DR (clone LN3,
eBioscience, San Diego CA, USA) antibodies and we
analyzed the proportion of CD16+ monocytes using a
flow cytometer.
Detection of IL-10 receptor expression
Heparinized whole blood cells from four healthy volun-
teers were stained with PE-Cy7-conjugated anti-CD14
(clone M5E2, BD Pharmingen), V450-conjugated anti-
CD16 (clone 3G8, BD Horizon), and APC-conjugated
anti-IL-10 receptor antibodies (clone 3F9, Biolegend,
San Diego CA, USA), and the expression levels of IL-10
receptor on the CD14brightCD16- monocyte subset was
evaluated.
IL-10 neutralization assay
CD14brightCD16- monocytes (2.5 × 105/500 μL) from the
peripheral blood of four healthy volunteers were incu-
bated with 25 ng/mL IL-10. In some experiments, anti-IL-
10 receptor antibody (5 μg/mL) (clone 3F9, Biolegend) or
rat IgG2aκ (5 μg/mL) to an irrelevant antigen (clone
RTK2758, Biolegend) was added to the cultures. CD16 ex-
pression on monocytes was then measured.
Statistical analysis
We used commercial statistical software (JMP 11 sys-
tem®, SAS Institute Inc., Cary NC, USA). The Wilcoxon
rank sum test was used to assess the statistical signifi-
cance of differences between groups. Correlation be-
tween two continuous variables was analyzed using
Spearman’s rank correlation coefficient. Dunn’s test was
used for multiple comparison procedures. A p value
<0.05 was considered statistically significant.
Results
Clinical characteristics of the patients with RA
Baseline characteristics of the 35 patients are shown in
Table 1. A total of 68.6% were RF-positive and 61.8%
were ACPA-positive. The mean DAS28-ESR score of the
patients was 4.83 ± 0.91. The mean MTX dose at
12 weeks was 10.8 mg/week (8–16). The mean DAS28-
ESR decreased from 4.83 at baseline to 3.53 at 12 weeks
(p < 0.001) (Table 2). Other clinical parameters also sig-
nificantly decreased, as shown in Table 2.
Proportions of each monocyte subset
Figure 1 shows the three monocyte subsets of periph-
eral blood cells from patients with RA at baseline and
healthy volunteers. The proportion of CD14brightCD16+
monocytes in patients with RA was significantly higher
than that in healthy volunteers (mean 14.0 ± 7.0% vs.
7.4 ± 2.2%), while that of CD14dimCD16+ monocytes
did not differ between the two groups (mean 7.3 ± 4.5%
vs. 8.1 ± 4.9%). In contrast, the CD14brightCD16- popu-
lation was significantly decreased in patients with RA
Table 1 Baseline characteristics of patients with rheumatoid
arthritis at baseline
Total (n = 35)
Mean age, years 59.80 ± 12.64
Female, n (%) 29 (82.9)
Disease duration, months 41.9 ± 76.2
CRP, mg/dL 0.64 ± 0.59
ESR, mm/h 35.7 ± 20.0
DAS28-ESR 4.83 ± 0.91
DAS28-CRP 4.02 ± 0.90
MMP-3 (ng/mL) 100.3 ± 84.8
RF-positive, n (%) 24 (68.6)
ACPA-positive, n (%) 21 (61.8)
SDAI 18.99 ± 9.22
CDAI 18.35 ± 9.03
HAQ 0.85 ± 0.68
CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS-28 disease activity
score in 28-joint count, MMP-3 matrix metalloproteinase-3, RF rheumatoid factor,
ACPA anti-cyclic citrullinated peptide antibody, SDAI simplified disease activity
index, CDAI clinical disease activity index, HAQ health assessment questionnaire
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(mean 72.1 ± 9.9% vs. 79.8 ± 5.7%) compared to healthy
volunteers.
After 12 weeks of MTX treatment, the proportion of
the CD14brightCD16+ population had significantly de-
creased from 14.0% to 10.9% and that of
CD14brightCD16- monocytes had significantly increased
from 72.2% to 77.6% in the patients with RA, while there
was no significant difference in the proportion of
CD14dimCD16+ monocytes between baseline and
12 weeks (Table 2).
Association between clinical parameters
and monocyte subsets
The association between CD14brightCD16-/CD14brightCD16+
monocytes and clinical parameters is shown in Fig. 2.
The proportion of CD14brightCD16- monocytes was
significantly and negatively correlated (Fig. 2a), while
that of CD14brightCD16+ monocytes was significantly
and positively correlated, with DAS28-ESR at baseline
(Fig. 2b). These results indicate that CD14brightCD16+
monocytes were positively correlated and CD14brightCD16-
monocytes were negatively correlated with RA activity. The
CD14brightCD16+ monocyte subset was also correlated with
other parameters such as CDAI, SDAI and CRP. Accord-
ingly, we utilized DAS28-ESR as a representative indicator
for the following analysis.
Association between each monocyte subset and serum
cytokine concentration
Among the ten serum inflammatory cytokines, levels of
IL-6, IL-8 and IL-10 at baseline were significantly
higher in patients with RA than in healthy volunteers
(Table 3). These cytokines were positively correlated
with DAS28-ESR (Fig. 3a). Moreover, the proportion of
CD14brightCD16+ monocytes was significantly and posi-
tively correlated with serum IL-6, IL-8, and IL-10
(Fig. 3b).
IL-10 induces surface CD16 expression on monocytes in
vitro
To investigate how those cytokines contribute to CD16
expression on monocytes, we isolated CD14brightCD16-
monocytes from five healthy volunteers and cultured the
cells with IL-6, IL-8, IL-10, or M-CSF for 14 hours in
vitro. We attempted to stimulate CD16 expression with
M-CSF as described in previous reports [12, 17]. Mean
purity of the CD14brightCD16- subset was 96.8%.
Remarkably, the expression of CD16 on the cells was
strongly and significantly increased with IL-10 for
14 hours, whereas M-CSF, IL-6, and IL-8 did not induce
CD16 expression significantly (Fig. 4a and b). To assess
Table 2 Changes in disease activity and the proportion of
monocyte subsets in patients with rheumatoid arthritis (n = 35)
at baseline and following 12 weeks of methotrexate treatment
Baseline 12 weeks p value
Disease activity parameters
DAS28-ESR 4.83 ± 0.91 3.53 ± 1.25 <0.001
SDAI 18.99 ± 9.87 10.24 ± 7.77 <0.001
CDAI 18.35 ± 9.03 9.84 ± 7.55 <0.001
ESR 35.7 ± 20.0 27.2 ± 23.4 0.0040
CRP 0.64 ± 0.59 0.35 ± 0.59 0.031
Monocyte subsets
CD14brightCD16- monocytes (%) 72.16 ± 9.87 77.57 ± 9.36 0.0042
CD14brightCD16+ monocytes (%) 13.96 ± 7.02 10.89 ± 7.25 0.0019
CD14dimCD16+ monocytes (%) 8.14 ± 4.84 6.41 ± 4.20 0.0619
Statistical analysis, Wilcoxon rank sum test. DAS-28 disease activity score in
28-joint count, SDAI simplified disease activity index, CDAI clinical disease
activity index, ESR erythrocyte sedimentation rate, CRP C-reactive protein.
Fig. 1 Proportions of CD14brightCD16+, CD14dimCD16+, and CD14brightCD16- monocytes in peripheral blood obtained from patients with
rheumatoid arthritis (RA) and from healthy volunteers at baseline (0 W) and 12 weeks (12 W). CD14brightCD16-/CD14brightCD16+/CD14dimCD16+
monocytes were identified by flow cytometry. The proportion of the three subsets of monocytes in patients with RA at baseline and 12 weeks
(n = 35) was compared with that in healthy volunteers (HV) (n = 14). Statistical analysis, Wilcoxon rank sum test. Proportions of CD14brightCD16-
and CD14brightCD16+ were significantly different. N.S. not significant
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equivalence to CD14brightCD16+ cells generated from
CD14brightCD16- classical monocytes, we analyzed
HLA-DR expression on the cultured cells by flow cy-
tometry, because the mean fluorescence intensity
(MFI) of CD14brightCD16+ monocytes is higher than
that of CD14brightCD16- monocytes [14, 18]. The MFI
of the HLA-DR on CD14brightCD16+ cells cultured
with IL-10 was higher than that of HLA-DR on
CD14brightCD16- cells without IL-10 (data not shown),
and increased almost as much as that of
CD14brightCD16+ monocytes in peripheral blood,
confirming that ex vivo CD14brightCD16+ cells gener-
ated from CD14brightCD16- monocytes had HLA-DR
expression identical to that of native CD14brightCD16+
cells.
We then confirmed the surface expression level of IL-
10 receptor on CD14brightCD16- monocytes. As a result,
more than 90% of the cells were IL-10 receptor-positive
(Fig. 5a). When CD14brightCD16- monocytes were incu-
bated with graded concentrations of IL-10 (1–50 ng/
mL), the proportion of CD16 expression on monocytes
increased in a dose-dependent manner with 1–25 ng/mL
Fig. 2 Correlation between the proportion of CD14brightCD16-/CD14brightCD16+ monocytes and clinical parameters at baseline in patients with
rheumatoid arthritis (RA) (n = 35). CD14brightCD16-/CD14brightCD16+ monocytes were identified by flow cytometry. The association between the
proportion of CD14brightCD16- (a)/ CD14brightCD16+ (b) monocytes and clinical parameters is shown. Statistical analysis, Spearman’s rank
correlation. r: correlation coefficient. DAS-28 disease activity score in 28-joint count, SDAI simplified disease activity index, CDAI clinical disease ac-
tivity index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody
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of IL-10 (Fig. 5b). There was almost the same enhanced
level of CD16 on the cells when the cells were cultured
with 50 ng/mL of IL-10. To confirm the direct effect of
IL-10 through the IL-10 receptor, we further conducted
a neutralization assay using anti-IL-10 receptor blocking
antibody. As a result, the enhanced level of CD16 on the
cells (18.3 ± 17.1%, p = 0.047) by IL-10 was significantly
suppressed by adding anti-IL-10 receptor antibody (0.19
± 0.19%), whereas isotype control (rat IgG2aκ) did not
suppress that enhancement (15.3 ± 10.5%, p = 0.047)
(Fig. 5c). These results indicate that cell signaling
through the IL-10 receptor contributes to regulate CD16
expression on monocytes.
Discussion
In this study, we demonstrate that circulating
CD14brightCD16+ monocytes are increased in patients
with RA in the active phase and decrease after MTX
treatment in a manner that correlates with decreasing
disease activity. Moreover, this monocyte subset is asso-
ciated with expression of inflammatory cytokines in per-
ipheral blood, and the cytokine IL-10, which is increased
in patients with RA, induces CD16 expression on mono-
cytes. These results suggest that CD14brightCD16+
monocytes play a role in the pathogenesis of RA, and
that IL-10 is a key cytokine in the regulation of CD16
expression.
Although an increase in CD14brightCD16+ monocytes
in patients with RA has been reported [14], the possibil-
ity of correlation between CD14brightCD16+ monocytes
and cytokines in untreated patients with active RA has
Table 3 Serum levels of inflammatory cytokines at baseline in
patients with rheumatoid arthritis (RA) and healthy volunteers
RA (n = 35) HV (n = 14) p value
GM-CSF 0.089 (0–0.28) 0 (0–0.45) 0.37
IFN-γ 1.31 (0.87–2.04) 1.17 (0.80–3.19) 0.68
IL-1β 0.027 (0–0.12) 0 (0–0.18) 0.74
IL-10 1.39 (0.98–2.16) 0.95 (0.55–1.29) 0.017
IL-12 0.70 (0.38–1.06) 0.53 (0.21–0.99) 0.21
IL-2 0.19 (0.046–0.30) 0.13 (0–0.22) 0.16
IL-6 3.19 (1.36–6.95) 0.51 (0.35–1.09) 0.0005
IL-8 13.77 (10.81–20.53) 10.90 (5.44–14.21) 0.019
TNF-α 3.75 (2.55–4.61) 3.48 (2.70–4.58) 0.99
M-CSF 164.84 (107.93–266.70) 157.82 (141.32–194.77) 0.82
Data presented as median in pg/mL (interquartile range). HV healthy
volunteers, GM-CSF granulocyte-macrophage colony-stimulating factor, IFN-γ
interferon-γ, M-CSF macrophage colony-stimulating factor. Statistical analysis,
Wilcoxon rank sum test
Fig. 3 Correlation between serum cytokines (IL-6, IL-8, and IL-10) and the proportion of CD14brightCD16+ monocytes at baseline in patients with
rheumatoid arthritis (n = 35), by 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR). Statistical analysis, Spearman’s
rank correlation coefficient. r: correlation coefficient
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not yet been investigated. Previous studies have not
ruled out any influence of treatment on cytokine and
disease activity, because the patients with RA in these
studies were not treatment-naïve. Our results support
previous observations [14] and show that the proportion
of CD14brightCD16+ monocytes is increased in
treatment-naïve patients with active RA compared to
healthy controls, and is positively correlated with disease
activity in these patients.
We further showed that the CD14brightCD16- popula-
tion was negatively correlated with RA disease activity.
Notably, the proportion of CD14brightCD16+ monocytes
decreased and that of CD14brightCD16- monocytes in-
creased when the patients received MTX treatment.
Though the function of CD14brightCD16+ monocytes
in RA is not still clarified, this population may be in-
volved in the pathogenesis of RA in accordance with
our findings that CD14brightCD16+ monocytes de-
creased after MTX treatment. It has been shown that
MTX inhibits inflammatory cytokine production [19]
and cell proliferation in vitro, and to induce apoptosis
of immune cells [20], but it has not been found to in-
hibit a specific subset of monocytes. One of the reasons
for the decreased proportion of CD14brightCD16+
monocytes after MTX treatment was probably second-
ary to a phenomenon derived from the improvement in
RA disease activity.
It is reported that M-CSF plays an important role in the
introduction of CD14brightCD16+ monocytes. Anti-M-CSF
antibody caused a decrease in circulating CD14brightCD16+
and CD14dimCD16+ monocytes in a clinical trial in two pa-
tients with active RA [17]. Moreover, M-CSF and IFN-γ
therapy has been found to induce CD16 expression on
circulating monocytes in patients with cancer or lymphoma
[21]. CD16 expression has been shown to be induced in
monocytes with culture of whole PBMCs with M-CSF or
IL-10 on CD14brightCD16- monocytes in vitro [12].
Although this report may indicate a possible direct role for
cytokines, it did not exclude interactions with other cell
subsets among the PBMCs. In our study, using highly
purified CD14brightCD16- monocytes, we clearly showed
that IL-10, but not M-CSF, directly induces CD16 expres-
sion in CD14brightCD16- monocytes. In addition, we
proved that the enhancement of CD16 expression on
CD14brightCD16- monocytes required the interaction with
IL-10 and IL-10 receptor by a neutralization assay with
anti-IL-10 receptor antibody.
It is well-known that IL-10 plays a crucial role, such as
anti-inflammatory and/or pro-inflammatory roles in the
pathogenesis of RA. IL-10 has been shown to inhibit pro-
duction of IL-6, TNF-α, and GM-CSF from immune cells
[22], and to enhance B cell differentiation to cells secreting
IgG, IgM, and IgA [23, 24], resulting in increased RF and
IgG-RF production by B cells in peripheral blood.
Fig. 4 CD16 surface expression by CD14brightCD16- monocytes induced by IL-10. CD14brightCD16- monocytes from healthy volunteers (n = 5) were
stimulated with M-CSF (100 ng/mL), IL-10 (25 ng/mL), IL-6 (100 ng/mg), or IL-8 (20 ng/mL) for 14 hours. CD16 expression on CD14brightCD16-
monocytes was evaluated by flow cytometry. a Representative dot plots of CD14 and CD16 expression by monocytes after stimulation with
macrophage colony-stimulating factor (M-CSF), IL-10, IL-6, or IL-8 for 14 hours. b CD16 expression by monocytes in healthy volunteers (n = 5). Bars
show the median ± SD. Statistical analysis, Dunn’s test
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Moreover, IL-10 is localized to the synovial membrane lin-
ing layer, the site of monocyte migration, and inhibits pro-
inflammatory cytokines in RA [25]. In this study, we dem-
onstrated that serum IL-10 in patients with RA was sig-
nificantly elevated compared with healthy volunteers, and
was correlated with disease activity.
IL-10 is secreted by many kinds of cells such as T-
cells, B-cells, macrophages, dendritic cells, natural killer
cells, and monocytes themselves [26–28]. It is reported
that CD16 expression on monocytes is maintained by
IL-10 production by human naïve CD4+ T cells [29].
The function of CD14brightCD16+ monocytes may be
regulated by these cells producing IL-10. IL-10 tended
to decrease in patients with RA with decreasing
CD14brightCD16+ monocytes after 12 weeks of treat-
ment. IL-10 may play a role in the induction of CD16 on
monocytes in patients with RA.
We note two limitations to our study. First, the num-
ber of patients was relatively small, albeit large enough
to provide statistically significant data. Second, we did
not show that CD14brightCD16+ monocytes are directly
associated with inflammatory cytokines in RA in vivo.
Production of IL-6 and TNF-α in CD14brightCD16+ mono-
cytes was not higher than that in CD14brightCD16-mono-
cytes (Additional file 1). We thought that CD14brightCD16+
monocytes could exert both inflammatory and anti-
inflammatory effects, and which effect’s dominance would
depend on cells producing IL-10. The functions of these
monocytes in RA will need to be clarified in future studies.
Conclusions
In conclusion, we have shown that CD14brightCD16+
monocyte proportions correlate with disease activity in
patients with RA, and that CD16brightCD14+ monocytes
are induced by IL-10 but not by other cytokines upregu-
lated in serum from patients with RA. Our results suggest
that CD16brightCD14+ monocytes are possibly involved in
the pathogenesis of RA and that IL-10 should be a key
cytokine that regulates CD16 expression in monocytes.
Fig. 5 Inhibition of CD16 expression on monocytes by blockade of IL-10 receptors. a A representative of mean fluorescence intensity shows
surface expression of IL-10 receptors using allophycocyanin (APC)-conjugated anti-IL-10 receptor and rat IgG2aκ antibodies on CD14brightCD16-
monocytes. b CD14brightCD16- monocytes from healthy volunteers (n = 4), stimulated with various concentrations of IL-10 (0, 1, 10, 25 ng/mL)
for 14 hours. c CD14brightCD16- monocytes from healthy volunteers stimulated with IL-10 (25 ng/mL), anti-IL-10 receptor antibody (5 μg/mL),
and/or rat IgG2aκ (5 μg/mL). Effect of IL-10 and anti-IL-10 receptor antibody (5 μg/mL) on CD16 expression of monocytes incubated for
14 hours is shown. The median of CD16 expression in monocytes was 0.06% and 0.13% when incubated with nothing or IL-10 + anti-IL-10 receptor,
respectively. Bars (b, c) show the median ± SD. Statistical analysis, Dunn’s test
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Abbreviations
ACPA: anti-cyclic citrullinated peptide antibody; APC: allophycocyanin;
CDAI: clinical disease activity index; CRP: C-reactive protein; DAS-28: disease
activity score in 28-joint count; ELISA: enzyme-linked immunosorbent assay;
ESR: erythrocyte sedimentation rate; FcγRIII: receptor for immunoglobulin
gamma Fc region III; FcγRs: Fcγ receptors; GM-CSF: granulocyte-macrophage
colony-stimulating factor; HAQ: health assessment questionnaire;
HLA: human leukocyte antigen; IFN: interferon; Ig: immunoglobulin;
IL: interleukin; IQR: interquartile range; M-CSF: macrophage colony-stimulating
factor; MFI: mean fluorescence intensity; MMP-3: matrix metalloproteinase-3;
MTX: methotrexate; PE: phycoerythrin; RA: rheumatoid arthritis; RF: rheumatoid
factor; SDAI: simplified disease activity index; TNF: tumor necrosis factor
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